Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Assessment of Motor Reserve in the Preclinical Stages of Dementia

3 de junio de 2026 actualizado por: Antonio Cerasa, Istituto per la Ricerca e l'Innovazione Biomedica

Assessment of Motor Reserve in the Preclinical Stages of Dementia.

Mild Cognitive Impairment (MCI) is a clinical condition associated with an increased risk of progression to dementia. Although cognitive alterations have traditionally been the main focus of investigation, growing evidence suggests that motor changes may also emerge during the early stages of cognitive decline and may represent potential preclinical indicators of disease.

In this context, the concept of motor reserve has emerged as a construct of increasing interest, although it remains insufficiently defined. Understanding how motor characteristics may contribute to an individual's ability to compensate for or modulate the effects of cognitive decline could provide new insights into the mechanisms involved in the early stages of dementia.

Therefore, the present monocentric observational study aims to further investigate the concept of motor reserve in healthy individuals and in patients with Mild Cognitive Impairment (MCI) through a multidimensional approach based on clinical, neuropsychological, behavioral, and kinematic assessments. In particular, standardized motor tasks and quantitative movement analyses using a sensor-based medical device will be employed to objectively characterize motor performance.The study plans to recruit approximately 200 participants, including healthy individuals and patients with MCI, enrolled at the Neuropsychology Outpatient Clinic of the Neurology Unit of the University Hospital "Renato Dulbecco" in Catanzaro. In the healthy group, the relationship between motor reserve and motor performance will be investigated, while in patients with MCI the relationship between cognitive reserve, motor reserve, clinical and neuropsychological status, and motor performance will be explored.

The findings of this study may contribute to a broader and more operational definition of motor reserve and support the identification of potential motor biomarkers associated with early cognitive decline. These findings may ultimately contribute to the development of innovative strategies for the early detection and monitoring of conditions at risk of progression to dementia.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Estimado)

200

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Domenico co Bosco, Medical Doctor
  • Número de teléfono: 0961/883021
  • Correo electrónico: nico.bosco@libero.it

Ubicaciones de estudio

    • Catanzaro
      • Catanzaro, Catanzaro, Italia, 88100
        • Reclutamiento
        • Azienda Ospedaliera "Renato Dulbecco"
        • Contacto:
          • Domenico Bosco, Medical Doctor
          • Número de teléfono: 0961/883021
          • Correo electrónico: nico_bosco@libero.it

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

The study population will consist of approximately 200 participants divided into two groups: 100 patients with Mild Cognitive Impairment (MCI) and 100 healthy control subjects. Participants will be recruited at the Neuropsychology Outpatient Clinic of the Neurology Unit, University Hospital "Renato Dulbecco", Pugliese Hospital, Catanzaro, Italy. MCI patients will be included according to international NIA-AA diagnostic criteria, while healthy subjects must show normal performance on neuropsychological screening. All participants will undergo clinical, anamnestic, and neuropsychological evaluation, followed by motor reserve assessment and kinematic evaluation at the IBSBC-CNR laboratories in Catanzaro using standardized motor tasks and a CE-marked sensor glove medical device. Written informed consent will be obtained from all participants or a legal representative, when applicable.

Descripción

Inclusion Criteria:

  • Patients with Mild Cognitive Impairment (MCI) group

    • Diagnosis of MCI according to the international criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA) (Albert et al., 2011; McKhann et al., 2011).
    • Age between 40 and 85 years.
    • Native Italian speaker or sufficient Italian language proficiency to understand the tests.
    • Signed informed consent provided by the participant or by a legal representative.
  • Healthy subjects group

    • Normal performance on the neuropsychological screening assessment. Age between 40 and 85 years.
    • Native Italian speaker or sufficient Italian language proficiency to understand the tests.
    • Signed informed consent.

Exclusion Criteria:

  • Patients with Mild Cognitive Impairment (MCI) group

    -History of psychiatric or neurological disorders not attributable to MCI. Use of psychotropic medications.

  • Healthy subjects group

    • History of psychiatric or neurological disorders.
    • Use of psychotropic medications.
    • Disabling medical comorbidities or medical conditions interfering with motor function.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Controles saludables
Participants will undergo a multidimensional assessment protocol aimed at investigating motor reserve in healthy individuals and patients with (MCI). The assessment will include clinical and neuropsychological evaluations, standardized motor tasks, and quantitative kinematic movement analysis using a sensor glove classified as a medical device, designed to record objective motor parameters during task execution. The collected measures will be used to characterize motor performance and to analyze its relationship with cognitive reserve, clinical status, and neuropsychological functioning. No therapeutic intervention or experimental treatment will be administered. All procedures will be performed exclusively for observational research purposes.
*Patients with MCI*
Participants will undergo a multidimensional assessment protocol aimed at investigating motor reserve in healthy individuals and patients with (MCI). The assessment will include clinical and neuropsychological evaluations, standardized motor tasks, and quantitative kinematic movement analysis using a sensor glove classified as a medical device, designed to record objective motor parameters during task execution. The collected measures will be used to characterize motor performance and to analyze its relationship with cognitive reserve, clinical status, and neuropsychological functioning. No therapeutic intervention or experimental treatment will be administered. All procedures will be performed exclusively for observational research purposes.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Finger Tapping Metrics
Periodo de tiempo: Baseline (single assessment)
Motor performance is assessed using a sensor-engineered glove that records the contact events between the thumb and the four fingers (index, middle, ring, little) on each hand independently, providing finger-level timing parameters for each sequence of taps.
Baseline (single assessment)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2026

Finalización primaria (Estimado)

1 de septiembre de 2026

Finalización del estudio (Estimado)

1 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de junio de 2026

Publicado por primera vez (Actual)

8 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 114/2026

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .